Avalo Therapeutics, Inc. (AVTX) Dividend History

Company News

• Avalo Therapeutics to Participate in Upcoming Investor Conferences

  Avalo Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences to discuss its lead asset AVTX-009, a monoclonal antibody targeting inflammatory diseases.

  GlobeNewswire Inc.
• Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?

  Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.

  Zacks Investment Research

  Featured Companies: ANNX
• Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

  Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa (HS) and additional updates. In March, Avalo Therapeutics announced the acquisition of a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, originally developed by Eli Lilly And Co (NYSE:LLY). Avalo announced a private placement of $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. Oppenheimer says that the company is preparing to advance ‘009 for Phase 2 development in hidradenitis suppurativa (HS), showing confidence in its potential. While topline data won’t be available until 2026, there’s consideration to also ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: ABBV LLY
• Top 3 Myths About Trading Penny Stocks

  Are these myths about penny stocks true? The post Top 3 Myths About Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: ICU